SCHEMBL266161

SCHEMBL266161

FC(F)Oc1ccc(I)cc1OC(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 11/20 0.38
PDE4B Q07343 7/20 0.38
PDE4D Q08499 7/20 0.38
PDE4C Q08493 6/20 0.38
PDE3B Q13370 2/20 0.33
PDE3A Q14432 2/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SLC6A4 P31645 1/20 0.33
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31098670 1.00 PDE4A (0.38) PDE4APDE4BPDE4DPDE4CPDE3B
SCHEMBL28651200 0.90 PDE4A (0.35) PDE4APDE4BPDE4DPDE4CPDE3B
SCHEMBL4139400 0.83 RAB9A (0.43) PDE4APDE4BPDE4DPDE4CLMNA
SCHEMBL12548655 0.83 GRIN2B (0.37) ALDH1A1LMNASMN1; SMN2SLC6A4HTT
SCHEMBL4312443 0.81 ALDH1A1 (0.34) ALDH1A1TSHRMAPK1SLC6A4
SCHEMBL28650759 0.81 ERN1 (0.34) PDE4APDE4BPDE4DPDE4CALDH1A1
SCHEMBL2794945 0.81 ALDH1A1 (0.38) ALDH1A1TSHRMEN1MAPTKMT2A
SCHEMBL31342255 0.81 RXRA (0.35)
SCHEMBL265869 0.81 ALDH1A1 (0.38) ALDH1A1LMNASMN1; SMN2SLC6A4HTT
SCHEMBL17711299 0.81 RXRA (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133909-B2 Heteroaromatic monoamides as orexinin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2297102-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-03-23 EP disclosed
WO-2009153180-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPSR1 PDE4A 4084/4885PDE4B 4031/4885PDE4D 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.